HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.

AbstractSUMMARY:
We verified the possibility of collecting large amounts of peripheral blood stem cells (PBSCs) to support three courses of adjuvant high-dose dense chemotherapy (HDDC) with high-dose epirubicin, preceded by dexrazoxane, and high-dose paclitaxel, in patients with high-risk breast cancer (>/=9 positive nodes). The mobilizing regimen consisted of high-dose epirubicin 150 mg/m(2), preceded by dexrazoxane 1000 mg/m(2) (day 1), given in combination with paclitaxel 175 mg/m(2) (day 2), plus filgrastim. Of the 25 patients enrolled, one went off study due to a severe hypersensitivity reaction to paclitaxel, another did not undergo leukapheresis due to fever persistent after hematological recovery, while in 23 patients an adequate number of PBSCs was collected by a single leukapheresis. The median number of CD34+, CD34+/CD33-, and CD34+/CD38- cells collected per patient was 17 x 10(6)/kg, 13.4 x 10(6)/kg, and 1.5 x 10(6)/kg, respectively. Neutropenia was the only grade 4 toxicity and lasted a median of 3 days. High-dose epirubicin, preceded by dexrazoxane for the first time used in mobilizing regimen, and paclitaxel plus filgrastim are effective in releasing large amounts of PBSCs, which can then be safely employed to support multiple courses of HDDC.
AuthorsU De Giorgi, G Rosti, A Zaniboni, M Ballardini, M R Minzi, M Baioni, E Ferrari, L Zornetta, M Marangolo
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 32 Issue 3 Pg. 251-5 (Aug 2003) ISSN: 0268-3369 [Print] England
PMID12858195 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Epirubicin
  • Razoxane
  • Paclitaxel
  • Filgrastim
Topics
  • Adult
  • Antigens, CD (analysis)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use, toxicity)
  • Breast Neoplasms (complications, therapy)
  • Cell Count
  • Epirubicin (administration & dosage)
  • Female
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor (administration & dosage)
  • Hematopoietic Stem Cell Mobilization (adverse effects, methods)
  • Humans
  • Leukapheresis (standards)
  • Middle Aged
  • Neutropenia (chemically induced)
  • Paclitaxel (administration & dosage)
  • Razoxane (administration & dosage)
  • Recombinant Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: